0000899243-19-030273.txt : 20191231 0000899243-19-030273.hdr.sgml : 20191231 20191231160532 ACCESSION NUMBER: 0000899243-19-030273 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191227 FILED AS OF DATE: 20191231 DATE AS OF CHANGE: 20191231 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCCORMICK FRANK CENTRAL INDEX KEY: 0001257809 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 191319529 MAIL ADDRESS: STREET 1: C/O EXELIXIS INC STREET 2: 170 HARBOR WAY CITY: S SAN FRANCISCO STATE: CA ZIP: 94083-0511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-27 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001257809 MCCORMICK FRANK C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 0 1 0 0 Chairman of Oncology Common Stock 2019-12-27 4 S 0 25531 36.371 D 1335895 D Common Stock 2019-12-27 4 S 0 21656 36.846 D 1314239 D Common Stock 2019-12-27 4 S 0 3500 38.0906 D 1310739 D Common Stock 2019-12-27 4 S 0 13705 39.273 D 1297034 D Common Stock 2019-12-27 4 S 0 16858 40.1258 D 1280176 D Common Stock 2019-12-27 4 S 0 883 41.3132 D 1279293 D Common Stock 2019-12-27 4 S 0 617 42.2622 D 1278676 D Common Stock 2019-12-27 4 S 0 100 42.93 D 1278576 D Common Stock 2019-12-30 4 S 0 16250 35.744 D 1262426 D Common Stock 2019-12-30 4 S 0 900 36.8574 D 1261526 D This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019. Represents the weighted average sale price of the shares sold from $35.68 to $36.67 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all sales reported in footnotes 2 through 10. Represents the weighted average sale price of the shares sold from $36.68 to $37.50 per share. Represents the weighted average sale price of the shares sold from $37.72 to $38.71 per share. Represents the weighted average sale price of the shares sold from $38.77 to $39.765 per share. Represents the weighted average sale price of the shares sold from $39.77 to $40.76 per share. Represents the weighted average sale price of the shares sold from $40.77 to $41.76 per share. Represents the weighted average sale price of the shares sold from $41.87 to $42.84 per share. Represents the weighted average sale price of the shares sold from $35.36 to $36.31 per share. Represents the weighted average sale price of the shares sold from $36.5101 to $37.25 per share. /s/ Brian Stephenson, Attorney-in-Fact 2019-12-31